I also think that the European side of the business has exciting growth prospects. If the USA can still earn $40m a quarter on average, and Europe ever gets to $10m a quarter, then we have potentially $200m in sales a year.
Provided that the products remains relevant, and generics don't steal too much market share (which I don't think they will for Axiron 1.6%), then we could potentially see the $50m milestone paid next year. Let's just hope sales ramp up in Europe, where the regulators aren't as strict.
- Forums
- ASX - By Stock
- Axiron/androgel sales over last quarter.
ACR
acrux limited
Add to My Watchlist
0.00%
!
1.9¢

I also think that the European side of the business has exciting...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.747M |
Open | High | Low | Value | Volume |
1.9¢ | 1.9¢ | 1.9¢ | $5.562K | 292.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 381825 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 60000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 331825 | 0.019 |
3 | 381800 | 0.018 |
1 | 175000 | 0.017 |
1 | 66732 | 0.015 |
1 | 70000 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 60000 | 2 |
0.021 | 177000 | 1 |
0.022 | 18000 | 1 |
0.023 | 73278 | 3 |
0.024 | 254102 | 7 |
Last trade - 15.04pm 20/06/2025 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |